Circulating Tumor DNA Response In Urothelial Cancer

NCT ID: NCT07183319

Last Updated: 2026-02-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-19
• Study Completion Date: 2029-03-31

Brief Summary

The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab & Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).

Detailed Description

This study aims to evaluate the de-escalation of therapy in patients with metastatic urothelial carcinoma (mUC). Patients will begin treatment with first-line (1L) (PEV) per standard of care. After 24 weeks, patients will be assessed for disease progression. Those who demonstrate stable disease or ongoing disease radiographic response and a ≥50% reduction in circulating tumor DNA (ctDNA) levels will enter the de-escalation phase. This phase consists of transitioning from PEV to pembrolizumab monotherapy. If, during the de-escalation period, patients exhibit disease progression or increased toxicity, they will be rechallenged with PEV.

Conditions

Urothelial Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pembrolizumab & Enfortumab Vedotin (PEV)

Patients with metastatic urothelial carcinoma (mUC) will initiate first-line (1L) PEV therapy as the standard of care. At 24 weeks, radiographic imaging will be performed to evaluate disease status. Patients who exhibit either stable disease or ongoing radiographic response, accompanied by a ≥50% reduction in circulating tumor DNA (ctDNA) levels, will transition to pembrolizumab monotherapy as part of a treatment de-escalation strategy. Pembrolizumab will be continued until the occurrence of disease progression or unacceptable toxicity. In the event of progression or intolerance, patients will be re-challenged with first-line PEV therapy and continue treatment until completion of the study-defined treatment period.

Group Type: EXPERIMENTAL

Pembrolizumab & Enfortumab Vedotin (PEV)

Intervention Type: DRUG

Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.

Pembrolizumab

Intervention Type: DRUG

Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.

Pembrolizumab & Enfortumab Vedotin (PEV)

Intervention Type: DRUG

If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.

Interventions

Pembrolizumab & Enfortumab Vedotin (PEV)

Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.

Intervention Type: DRUG

Pembrolizumab

Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.

Intervention Type: DRUG

Pembrolizumab & Enfortumab Vedotin (PEV)

If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.

Intervention Type: DRUG

Other Intervention Names

PADCEV; KEYTRUDA; PADCEV

Eligibility Criteria

Inclusion Criteria

• Have histologically documented unresectable, locally advanced, or metastatic urothelial carcinoma.
• Measurable disease according to the New Response Evaluation Criteria in Solid Tumors (RECIST v1.1)38

a. Participants with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy.

• Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment.
• Archival tumor tissue comprising muscle-invasive urothelial carcinoma, or a biopsy of metastatic urothelial carcinoma must be available for tumor-informed ctDNA analysis.
• Meets Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2.
• Adequate hematologic and organ function (Hb ≥ 8.0 g/dL; ANC ≥ 1.5x109 cells/L; CrCl ~30 mL/min; total bilirubin ≤ 1.5 mg/dL; ALT and AST within normal limits).

Exclusion Criteria

• Previously received enfortumab, vedotin, or other monomethyl auristatin E (MMAE)-based ADCs.
• Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor within 12 months.
• Has received anti-cancer treatment with chemotherapy, biologics, or investigational agents not otherwise prohibited by exclusion criterion 1-3 that is not completed within 28 days prior to cycle 1 day 1.
• Has uncontrolled diabetes or ≥ grade III peripheral neuropathy.
• Patient's estimated life expectancy is less than 12 weeks.
• Has untreated central nervous system metastases.
• Experiences ongoing clinically significant toxicity associated with prior treatment that has not resolved to ≤ Grade 1 or returned to baseline.
• Is currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal). Routine antimicrobial prophylaxis is permitted.
• Has known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
• Has history of another invasive malignancy requiring treatment within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy (excluding localized prostate cancer or basal cell carcinoma of skin or squamous cell carcinoma of the skin).
• Has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class IV within 6 months.
• Received radiotherapy within 2 weeks.
• Received major surgery (defined as requiring general anesthesia and >24-hour inpatient hospitalization) within 2 weeks.
• Known severe (≥ Grade 3) hypersensitivity to any EV excipient contained in the drug formulation of EV.
• Has active keratitis or corneal ulcerations.
• Has a history of autoimmune disease that has required systemic immunosupressive treatment in the past 2 years, or uncontrolled autoimmune disease.
• Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:

• Participants that received neoadjuvant chemotherapy with recurrence >12 months from completion of therapy are permitted.
• Participants that received adjuvant chemotherapy or ICPIs therapy following cystectomy with recurrence >12 months from completion of therapy are permitted.
• Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
• Has received prior allogeneic stem cell or solid organ transplant.
• Received a live attenuated vaccine within 30 days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Natera, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Oklahoma

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adanma Ayanambakkam, MD

Role: PRINCIPAL_INVESTIGATOR

University of Oklahoma

Locations

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Lead Onco Nurse

Role: CONTACT

SCC-IIT-Office@ouhsc.edu

405-271-8777

Adanma Ayanambakkam, MD

Role: CONTACT

Adanma-Ayanambakkam@ouhsc.edu

405-271-4022

Facility Contacts

Adanma Ayanambakkam, MD

Role: primary

Adanma-Ayanambakkam@ouhsc.edu

405-271-4022

Other Identifiers

OU-SCC-CT-READ

Identifier Type: -

Identifier Source: org_study_id